RSRyan William Stidham

Ryan William Stidham

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ryan William Stidham has a total of 264 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Artificial Intelligence for Gastroenterology Practice: A Modified Delphi Consensus

    by Seth A. Gross, Aasma Shaukat, Anita Afzali, Joseph C. Ahn, Jasmohan S. Bajaj, Jodie A. Barkin, Mohammad Bilal, Saurabh Chawla, Nayantara Coelho-Prabhu, Sarah M. Enslin, et al.

    INTRODUCTION: The American College of Gastroenterology assembled a multidisciplinary task force to evaluate the current state and future direction of artificial intelligence (AI) in gastroenterology, hepatology, and endoscopy leading to the development of consensus-based recommendations for responsible AI integration in clinical practice. METHODS: A total of 32 subject-matter experts and 12 industry partners, representing diverse practice settings and expertise, conducted subgroup literature reviews across 5 key areas (endoscopy, practice management clinical applications, training and education, inflammatory bowel disease and liver disease, ethics and equity). Draft statements were developed and rated on a 5-point Likert scale using a modified Delphi process. A consensus was set at ≥70% combined agreement. Nonconsensus items were revised and revoted electronically. RESULTS: A total of 43 statements, 40 (93%) reached consensus in round 1 and the remaining 3 achieved consensus after round 2. Evidence supports computer-aided detection improving adenoma detection rate and miss rate in controlled studies, with mixed real-world impact and insufficient long-term outcomes (e.g., interval colon cancer rate). Recommendations emphasize thorough validation and reduction of bias by heterogeneous Data sets. Outside endoscopy, ambient AI scribes, natural language processing (NLP)-enabled coding, workflow optimization, and previous authorization support show potential. Training recommendations endorse a structured AI curriculum while preserving independent procedural competence to avoid deskilling. In inflammatory bowel disease and hepatology, AI could help improve diagnostic accuracy, help predict risk of disease progression, and help guide therapy. Equity, governance, and reimbursement statements call for chain-of-custody data protections, specialty-society oversight, and payment models that reward quality and cost reduction. DISCUSSION: This consensus outlines how AI can augment rather than replace clinical expertise while promoting safety, transparency, interoperability, and equity. Priorities include pragmatic and prospective trials, multi-institutional data-sharing consortia, bias mitigation, and workforce training to enable trustworthy and clinically impactful AI adoption in gastroenterology, liver, and endoscopy care.


  • Artificial Intelligence Analysis of Endoscopy Outperforms Conventional Endoscopic Scoring for Agreement With Symptoms and Quality of Life in a Phase 3 Ulcerative Colitis Trial

    by Ryan W. Stidham, Lingrui Cai, Emily Wittrup, Michael Rice, Shrinivas Bishu, Anjali Jain, Mark T. Osterman, Kayvan Najarian

    INTRODUCTION: Ulcerative colitis (UC) disease assessment considers both mucosal healing and symptoms which can disagree. We compared the artificial intelligence (AI) endoscopic cumulative disease score (CDS) with the Mayo endoscopic score (MES) for agreement with symptoms and health related quality of life (HR-QoL) in UC. METHODS: Endoscopic video was obtained from TrueNorth, a 52-week phase 3 trial comparing ozanimod (OZA) with placebo (PBO) for UC. End of maintenance CDS was compared with endoscopically inactive (MES 0, 1) vs active (MES 2, 3) groups by partial Mayo remission (PMS, ≤2) and treatment using the Mann–Whitney U test. CDS and MES were compared with EuroQol 5 Dimension HR-QoL measures using the Kruskal-Wallis test. Low CDS cutoff for PMS remission used the Youden index, with agreement to PMS assessed using Cohen's κ. RESULTS: In 387 subjects, among endoscopically active subjects (MES 2, 3), the CDS was lower in those achieving PMS symptomatic remission (83.8 vs 186.9, P < 0.0001). EuroQol 5 Dimension had better agreement with CDS than MES (κ = 0.53 vs 0.44) and detected QoL differences within MES 2, 3 subjects for patient-reported health dimensions. Compared with low endoscopic maximum intensity (MES 0, 1), low-cumulative disease burden (CDS <40, area under the curve 0.85) had better agreement with PMS remission (κ = 0.57 vs 0.72). When defining adequate endoscopic criteria as PMS remission plus either low MES or low CDS, the difference between OZA vs PBO remission increased from 22.6% to 28.6%. DISCUSSION: AI-enabled endoscopic scoring has better agreement with symptomatic remission and HR-QoLs compared with MES and could quantitatively redefine adequate mucosal healing.


  • Artificial Intelligence for Quantifying Endoscopic Mucosal Ulceration in Crohn’s Disease

    by Lingrui Cai, Emily Wittrup, Cristian Minoccheri, Tadd K. Hiatt, Michael D. Rice, Shrinivas Bishu, Aleksandar Stojmirovic, Louis R. Ghanem, Kayvan Najarian, Ryan W. Stidham


  • Open Access

    Supervised Coupled Matrix-Tensor Factorization (SCMTF) for Computational Phenotyping of Patient Reported Outcomes in Ulcerative Colitis

    by Cristian Minoccheri, Sophia Tesic, Kayvan Najarian, Ryan Stidham

    Phenotyping is the process of distinguishing groups of patients to identify different types of disease progression. A recent trend employs low-rank matrix and tensor factorization methods for their capability of dealing with multi-modal, heterogeneous, and missing data. Symptom quantification is crucial for understanding patient experiences in inflammatory bowel disease, especially in conditions such as ulcerative colitis (UC). However, patient-reported symptoms are typically noisy, subjective, and significantly more sparse than other data types. For this reason, they are usually not included in phenotyping and other machine learning methods. This paper explores the application of computational phenotyping to leverage Patient-Reported Outcomes (PROs) using a novel supervised coupled matrix-tensor factorization (SCMTF) method, which integrates temporal PROs and temporal labs with static features to predict medication persistence in ulcerative colitis. This is the first tensor-based method that is both supervised and coupled, it is the first application to the UC domain, and the first application to PROs. We use a deep learning framework that makes the model flexible and easy to train. The proposed method allows us to handle the large amount of missing data in the PROs. The best model predicts changes in medication 8 and 20 months in the future with AUCs of 0.853 and 0.803 on the test set respectively. We derive interpretable phenotypes consisting of static features and temporal features (including their temporal patterns). We show that low-rank matrix and tensor based phenotyping can be successfully applied to the UC domain and to highly missing PRO data. We identify phenotypes useful to predict medication persistence - these phenotypes include several symptom variables, showing that PROs contain relevant infromation that is usually discarded.

  • Circulating Extracellular Matrix Products as Indicators of Disease Burden and Predictors of Disease Course in Ulcerative Colitis

    by Anja Poulsen, Marta Sorokina Alexdóttir, Lene Buhl Riis, Martin Pehrsson, Lars Tue Sørensen, Peter-Martin Krarup, Anne-Christine Bay-Jensen, Morten A Karsdal, Ryan W Stidham, Johan Burisch, et al.

    Background: Ulcerative colitis (UC) is characterized by recurrent inflammation and challenging disease monitoring, with invasive endoscopy as the primary diagnostic tool despite the inadequacy of standard noninvasive biomarkers. This study evaluates serum extracellular matrix (ECM) fragments, which reflect the remodeling of mucosa and submucosa, as potential indicators of disease burden and treatment efficacy. We aim to determine whether serum ECM levels correlate with the extent and severity and predict treatment response. Methods: We conducted a prospective study comparing serum ECM formation (PRO-C3, PRO-C7, PRO-C11, PRO-C22), turnover (PRO-C4), and degradation markers (C1M, C3M, C4M, C7M) at Weeks 0, 12, and 24 in 49 UC patients and 50 healthy controls measured by enzyme-linked immunosorbent assay. Results: ECM biomarkers, notably PRO-C11, differentiated UC patients from controls (area under the curve [AUC] 0.77), and PRO-C3 predicted endoscopic treatment response vs nonresponse (AUC 0.74). C7M separated moderate from severe disease in endoscopy (AUC 0.74) as well as mild from severe disease (AUC 0.84), as did the ratio C7M/PRO-C7 (AUC 0.82). Combining new and conventional markers, including hemoglobin, C-reactive protein, PRO-C3, and PRO-C22, achieved a combined AUC of 0.84 for predicting 24-week endoscopic response, adding index endoscopic activity increased the AUC to 0.92 compared to an AUC of 0.84 for endoscopy alone. Conclusions: Soluble ECM fragments reflect endoscopic disease severity and extent and are also predictive of therapeutic efficacy. They may as well reflect degenerative aspects of UC and may as such be future therapeutic targets aimed at prevention of intestinal damage.


  • Machine learning methods in automated detection of CT enterography findings in Crohn's disease: A feasibility study

    by Ashish P. Wasnik, Mahmoud M. Al-Hawary, Binu Enchakalody, Stewart C. Wang, Grace L. Su, Ryan W. Stidham